东阳光药(01558.HK)料中绩多赚六成股价回吐近8%
东阳光药(01558.HK)料中绩多赚逾60%,但该股继上周五创52周高位遇阻後,今天显着回吐,一举失守20天及10天线(40.92元及41.85元),最低见39.5元,现造39.8元,跌7.8%,成交急增至494万股,创逾三个月高,涉资逾2亿元。
东阳光药指,受惠核心产品可威之销售额持续增长、公司产品於全国医疗机构渗透率不断提升,以及持续加强在专业学术市场推广其产品,预计中期纯利按年增长逾60%。
按东阳光药去年中期纯利6.35亿人民币计算,今年中期纯利超过10.16亿人民币。不过,公司今年首季已赚7.76亿人民币,即次季只赚2.4亿人民币,按季倒退69%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.